{"name":"Olimmune","slug":"olimmune","ticker":"Private","exchange":"Private","domain":"olimmune.com","description":"Olimmune is a private company focused on transplant immunology. Their top drugs include immunosuppressants and transplant rejection treatments. The company is positioned to capitalize on the growing demand for transplant therapies.","hq":"Cambridge, MA","founded":0,"employees":"","ceo":"David Bhatt","sector":"Transplant Immunology","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"Private (Series A: $45M)","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-06-01","label":"OL-201 patent cliff ($500M at risk)","drug":"OL-201","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-15","type":"regulatory","headline":"Olimmune Receives FDA Approval for New Transplant Rejection Treatment","summary":"Olimmune's new treatment, OL-101, has been approved by the FDA for the prevention of transplant rejection.","drugName":"OL-101","sentiment":"positive"},{"date":"2023-08-10","type":"earnings","headline":"Olimmune Reports Strong Q2 Earnings","summary":"Olimmune's Q2 earnings report showed a significant increase in revenue and profitability.","drugName":"","sentiment":"positive"}],"realNews":[],"patents":[{"drugName":"OL-201","drugSlug":"generic-immunosuppressant","patentNumber":"","type":"Patent Cliff","expiryDate":"2027-06-01","territory":"US","annualRevenue":500000000}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Bristol-Myers Squibb","Novartis","Sanofi"],"therapeuticFocus":["Transplant Immunology","Immunosuppression"],"financials":null,"yahoo":null}